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AtherosclerosisIn the paper by Clancy et al., a model using human carotid ex-
plants evaluates the role of angiotensin receptor blockers (ARBs) on
cytokine release and extracellular signal regulated kinases (ERK1/2)
in human atherosclerosis [1]. The renin-angiotensin system (RAS)
plays an important role in vascular contraction and relaxation as
well as electrolyte balance in mammals. Work performed in mouse
models of atherosclerosis, has shown that the angiotensin receptor
1a (AT1aR) plays an important role in diet- and angiotensin II
(AngII)-induced atherosclerosis [2,3]. In humans, the ONTARGET
trial showed that ARBs could work as well as angiotensin con-
verting enzyme inhibitors (ACEi) without the side effects seenwith
ACEi [4]. Despite this, dual therapy with both classes of drugs, did
not show any beneﬁcial effects. In regards to atherosclerosis, clin-
ical trials comparing ARBs to other anti-hypertensives have been
conﬂicting [5,6], but this study helps to conﬁrm the role of ARBs as
drugs that can lower inﬂammation in the vessel wall.
An interesting ﬁnding in this paper was that other forms of in-
hibition of the RAS, through using an angiotensin analog ([Sar1,
Ile8]-AngII) or through angiotensin converting enzyme-2 (ACE2)
inhibition (DX600) did not show any effect on lowering inﬂam-
mation using this in vitro culture system. It was also shown that
AngII given exogenously to either human atheroma or a primary
cell mixed culture system did not have any overall effect onDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.06.011.
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involved in macrophage foam cell formation and decreasing CXCL5
expression enhances atherosclerosis in apolipoprotein e (ApoE/)
deﬁcient mice [7]. Future work to look at the RAS and other
angiotensin peptides on CXCL5 expression would be beneﬁcial to
understand. The authors have noted that the absence of these ef-
fects might be a result of other angiotensin peptides, such as
angiotensin (3e8)(AngIII), that might be binding to the AT1R and
inducing these anti-inﬂammatory effects. While this could deﬁ-
nitely be a factor, current interest has been to understand the
interaction that ARBs have on the AT1R. New information on biased
AT1R agonists has shown that these drugs can stimulate the
beta(b)-arrestin pathway without activating other second mes-
sengers, such as inositol triphosphate (IP3) or intracellular calcium.
Clancy et al., also indicate that losartan and irbesartan induced
differential effects on inﬂammation indicating that all ARBs are not
created equal [1]. It would be of interest to understand how these
ARBs induce similar or different conformational changes in the
AT1R and how signaling intermediates might be different among
different ARBs.
Another interesting feature to this paper was that the mitogen
kinase kinase 1/2 inhibitor, PD98059, also blocked the inﬂamma-
tory response in human atheroma. This block has been shown to
decrease ERK1/2 activation; however in these samples the protein
abundance was also decreased. This effect was also seen to occur
with irbesartan and it is puzzling how a G-protein coupled receptor
(GPCR) might mediate these effects? It is through gene transcrip-
tional regulation or possibly by manipulating the secretory ma-
chinery and processing in the endoplasmic reticulum and/or Golgi
apparatus? It is also possible to get ERK activation through the b-
arrestin pathway possibly indicating that this pathwaymay have an
important role in human atherosclerosis [8,9]. These results help to
bring about more interesting questions on the role of the RAS in
atherosclerosis and help to provide more insight on which ARBs
might be better in the treatment of RAS-related diseases.
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